Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
We aimed to evaluate the efficacy and safety of carboplatin plus weekly paclitaxel with bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC).



Patients with stage IIIB/IV or postoperative recurrent NSCLC (n=33) were treated with carboplatin (area under the curve of 6) on day 1; paclitaxel (80 mg/m2) on days 1, 8, and 15; and bevacizumab (15 mg/kg) on day 1 repeated every 4 weeks, for four to six cycles; followed by maintenance bevacizumab (15 mg/kg) every 3 weeks.



The overall response rate was 76%. The median progression-free survival and overall survival were 8.4 months and 22.2 months, respectively. Grade 3-4 toxicities included neutropenia in 55% of patients, anemia in 18%, febrile neutropenia in 12%, and anorexia in 9%. No treatment-related deaths were observed.



Carboplatin plus weekly paclitaxel with bevacizumab was effective and well tolerated by patients with advanced NSCLC.
Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan myamasanjp@yahoo.co.jp.
Masahiro
M
Yamasaki
Department of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Japan.
Isao
I
Murakami
Department of Respiratory Medicine, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Kikuo
K
Nakano
Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Mihoko
M
Doi
Department of Medical Oncology, Hiroshima City Asa Citizens' Hospital, Hiroshima, Japan.
Souichi
S
Kitaguchi
Department of Respiratory Medicine, JA Hiroshima General Hospital, Hiroshima, Japan.
Tomohiro
T
Kondo
Sakurai Clinic, Hiroshima, Japan.
Joji
J
Sakurai
Department of Molecular and Internal Medicine, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Noboru
N
Hattori
Department of Respiratory Medicine, Mihara Red Cross Hospital, Mihara, Japan.
Ken-Ichi
KI
Arita
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D064147:Febrile Neutropenia / Q000139:chemically induced; D005260:Female; D006801:Humans; D007239:Infections / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
Non-squamous non-small cell lung cancer; bevacizumab; carboplatin; phase II study; weekly paclitaxel